2002•The LancetRequires access

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein, Lloyd Mayer, Stefan Schreiber, Jean‐Frédéric Colombel, Daniel Rachmilewitz, Douglas C. Wolf, Allan David Olson, Weihang Bao, Paul J. Rutgeerts

Open publisher page 4,190 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 4190 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Infliximab, Crohn's disease, Placebo, Internal medicine, Clinical endpoint, Odds ratio, Randomized controlled trial

Back to paper search Browse research topics Original source

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial — Research Paper | ScholarLens